Back to Search
Start Over
Suivi thérapeutique pharmacologique du 5-fluorouracile : mise au point et recommandations du groupe STP-PT de la SFPT et du GPCO-Unicancer
- Source :
- Bulletin du Cancer, Bulletin du Cancer, John Libbey Eurotext, 2018, 105 (9), pp.790-803. ⟨10.1016/j.bulcan.2018.06.008⟩, Bulletin du Cancer, 2018, 105 (9), pp.790-803. ⟨10.1016/j.bulcan.2018.06.008⟩
- Publication Year :
- 2018
- Publisher :
- HAL CCSD, 2018.
-
Abstract
- International audience; Despite being 60-years old now, 5-FU remains the backbone of numerous regimen to treat a variety of solid tumors such as breast, head-and-neck and digestive cancers either in neo-adjuvant, adjuvant or metastatic settings. Standard 5-FU usually claims 15-40% of severe toxicities and up to 1% of toxic-death. Numerous studies show a stiff relationship between 5-FU exposure and toxicity or efficacy. In addition, 5-FU pharmacokinetics is highly variable between patients. Indeed, 80% of the 5-FU dose is catabolized in the liver by dihydropyrimidine dehydrogenase (DPD) into inactive compounds. It is now well established that DPD deficiency could lead to severe toxicities and, thus, require dose reduction in deficient patients. However, despite dosage adaptation based on DPD status, some patients may still experience under- or over-exposure, leading to inefficacy or major toxicity. The "Suivi thérapeutique pharmacologique et personnalisation des traitements" (STP-PT) group of the "Société française de pharmacologie et de thérapeutique" (SFPT) and the "Groupe de pharmacologie clinique oncologique" (GPCO)-Unicancer, based on the latest and most up-to-date literature data, recommend the implementation of 5-FU Therapeutic Drug Monitoring in order to ensure an adequate 5-FU exposure.
- Subjects :
- Cancer Research
medicine.medical_specialty
medicine.medical_treatment
5-fluorouracile
[SDV.CAN]Life Sciences [q-bio]/Cancer
Therapeutic drug monitoring
030226 pharmacology & pharmacy
03 medical and health sciences
Suivi thérapeutique pharmacologique
0302 clinical medicine
Pharmacokinetics
Toxicité
Dihydropyrimidine dehydrogenase
Medicine
Radiology, Nuclear Medicine and imaging
Digestive cancer
Gynecology
Recommandation
medicine.diagnostic_test
Toxicity
business.industry
Pharmacocinétique
Hematology
General Medicine
3. Good health
Regimen
Oncology
030220 oncology & carcinogenesis
Dose reduction
business
Adjuvant
Fluoropyrimidine
Subjects
Details
- Language :
- French
- ISSN :
- 00074551 and 17696917
- Database :
- OpenAIRE
- Journal :
- Bulletin du Cancer, Bulletin du Cancer, John Libbey Eurotext, 2018, 105 (9), pp.790-803. ⟨10.1016/j.bulcan.2018.06.008⟩, Bulletin du Cancer, 2018, 105 (9), pp.790-803. ⟨10.1016/j.bulcan.2018.06.008⟩
- Accession number :
- edsair.doi.dedup.....ab323410436cc1fa1b8e2de111af3f6e